Analyst rating coverage is not available for KALA yet.
12-MONTH PRICE TARGET
—
Average target across 0 active firms as of Nov 19, 2026 vs $3.31 current
Highest Target—
Average Target—
Lowest Target—
KALA analyst recommendation trends
86420
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Strong BuyBuyNeutralSellStrong Sell
RATING
JUN
JUL
AUG
SEP
OCT
NOV
Strong Buy
0
0
0
0
0
0
Buy
3
2
2
0
0
0
Neutral
1
1
1
0
0
0
Sell
0
0
0
0
0
0
Strong Sell
0
0
0
0
0
0
Total
4
3
3
0
0
0
As of Nov 19, 2026, 0 of 0 active firms rate KALA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
KALA EPS & revenue forecast
EPS · THIS QUARTER
$-0.32
Range $-0.32 – $-0.32 · 1 analysts · -82% YoY
Next period, 1 analysts expect Kala Pharmaceuticals Inc to earn $-0.32 a share (range $-0.32 – $-0.32), versus $-1.74 a year earlier. , growing to $-0.53 the year after.
REVENUE · THIS QUARTER
—
Range — – — · 1 analysts
Revenue is expected to reach — (range — – —)., rising to $0 next year.
Top analysts covering Kala Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on KALA.
#1
Graig Suvannavejh
Mizuho · Rank #239
Neutral
$75.00+2165.9% to target
Overall win rate
40%
+ Follow
#2
Yi Chen
HC Wainwright & Co. · Rank #350
Neutral
No targeton KALA
Overall win rate
34%
+ Follow
#3
Andreas Argyrides
Oppenheimer · Rank #380
Buy
$33.00+897.0% to target
Overall win rate
41%
+ Follow
#4
Aydin Huseynov
Ladenburg Thalmann · Rank #564
Buy
$600.00+18026.9% to target
Overall win rate
32%
+ Follow
KALA stock forecast FAQ
Who is the most accurate analyst covering KALA?+
Among analysts who currently cover KALA, Graig Suvannavejh of Mizuho has the strongest overall Quantellect track record (Rank #239). Their current call is Neutral with a $75.00 target.
What is Kala Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.32 per share (range $-0.32 – $-0.32) across 1 analysts, rising to $-0.53 the following year.
How much revenue is Kala Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is — (range — – —), growing to $0 next year.
Have analysts been upgrading or downgrading KALA lately?+
As of Nov 19, 2026, 0 of 0 active firms rate KALA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their KALA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.